View in EDS

LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors.

Saved in:
Bibliographic Details
Title: LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors.
Authors: Monaco KA; Bristol Myers-Squibb, Cambridge, Massachusetts., Delach S; Novartis Institutes for Biomedical Research, Cambridge, Massachusetts., Yuan J; Novartis Institutes for Biomedical Research, Cambridge, Massachusetts., Mishina Y; Novartis Institutes for Biomedical Research, Cambridge, Massachusetts., Fordjour P; Novartis Institutes for Biomedical Research, Cambridge, Massachusetts., Labrot E; Novartis Institutes for Biomedical Research, Cambridge, Massachusetts., McKay D; Ventus Therapeutics, Montreal, Quebec, Canada., Guo R; Novartis Institutes for Biomedical Research, Cambridge, Massachusetts., Higgins S; Novartis Institutes for Biomedical Research, Cambridge, Massachusetts., Wang HQ; Novartis Institutes for Biomedical Research, Cambridge, Massachusetts., Liang J; Novartis Institutes for Biomedical Research, Cambridge, Massachusetts., Bui K; Novartis Institutes for Biomedical Research, Cambridge, Massachusetts., Green J; Novartis Institutes for Biomedical Research, Cambridge, Massachusetts., Aspesi P; Novartis Institutes for Biomedical Research, Cambridge, Massachusetts., Ambrose J; Novartis Institutes for Biomedical Research, Cambridge, Massachusetts., Mapa F; Novartis Institutes for Biomedical Research, Cambridge, Massachusetts., Griner L; Novartis Institutes for Biomedical Research, Cambridge, Massachusetts., Jaskelioff M; Skyhawk Therapeutics, Waltham, Massachusetts., Fuller J; Novartis Institutes for Biomedical Research, Emeryville, California., Crawford K; AbSci, Vancouver, Washington., Pardee G; Novartis Institutes for Biomedical Research, Emeryville, California., Widger S; Novartis Institutes for Biomedical Research, Emeryville, California., Hammerman PS; Novartis Institutes for Biomedical Research, Cambridge, Massachusetts., Engelman JA; Novartis Institutes for Biomedical Research, Cambridge, Massachusetts., Stuart DD; Scorpion Therapeutics, Boston, Massachusetts., Cooke VG; Novartis Institutes for Biomedical Research, Cambridge, Massachusetts., Caponigro G; Novartis Institutes for Biomedical Research, Cambridge, Massachusetts. giordano.caponigro@novartis.com.
Source: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2021 Apr 01; Vol. 27 (7), pp. 2061-2073. Date of Electronic Publication: 2020 Dec 22.
Publication Type: Journal Article
Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1557-3265
DOI:10.1158/1078-0432.CCR-20-2563